Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer

Siang-Boon Koh; Leif W Ellisen

doi:10.1016/j.ccell.2021.11.001

Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer

Siang-Boon Koh, Leif W Ellisen

Research output: Contribution to journal › Article (Academic Journal) › peer-review

8 Citations (Scopus)

Abstract

Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC, and they reveal potential mechanisms of T cell activation and patterns of immune evolution that may inform future biomarkers of response and clinical benefit.

Original language	English
Pages (from-to)	1562-1564
Number of pages	3
Journal	Cancer Cell
Volume	39
Issue number	12
Early online date	8 Nov 2021
DOIs	https://doi.org/10.1016/j.ccell.2021.11.001
Publication status	Published - 13 Dec 2021

Bibliographical note

Publisher Copyright:
Copyright © 2021 Elsevier Inc. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ccell.2021.11.001

Handle.net

Persistent link

Cite this

@article{f8c5abfe2dd046fdaa03cf6b154f4d82,

title = "Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer",

abstract = "Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC, and they reveal potential mechanisms of T cell activation and patterns of immune evolution that may inform future biomarkers of response and clinical benefit.",

author = "Siang-Boon Koh and Ellisen, \{Leif W\}",

year = "2021",

month = dec,

day = "13",

doi = "10.1016/j.ccell.2021.11.001",

language = "English",

volume = "39",

pages = "1562--1564",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "12",

}

TY - JOUR

T1 - Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer

AU - Koh, Siang-Boon

AU - Ellisen, Leif W

PY - 2021/12/13

Y1 - 2021/12/13

N2 - Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC, and they reveal potential mechanisms of T cell activation and patterns of immune evolution that may inform future biomarkers of response and clinical benefit.

AB - Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC, and they reveal potential mechanisms of T cell activation and patterns of immune evolution that may inform future biomarkers of response and clinical benefit.

U2 - 10.1016/j.ccell.2021.11.001

DO - 10.1016/j.ccell.2021.11.001

M3 - Article (Academic Journal)

C2 - 34767761

SN - 1535-6108

VL - 39

SP - 1562

EP - 1564

JO - Cancer Cell

JF - Cancer Cell

IS - 12

ER -

Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer

Abstract

Bibliographical note

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this